Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial

Am J Clin Oncol. 1991 Oct;14(5):397-9. doi: 10.1097/00000421-199110000-00007.

Abstract

Fifteen evaluable patients with metastatic malignant melanoma who had received no prior chemotherapy were treated with high-dose cimetidine orally, 600 mg q.i.d. Although three patients had stable disease lasting 2-4 months, there were no objective responses. Median survival was 5.3 months (range 1-18 months). Toxicity was essentially negligible except for severe diarrhea in one patient and worsening liver function abnormalities in another. High-dose cimetidine does not have any significant activity in metastatic melanoma.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Cimetidine / adverse effects
  • Cimetidine / therapeutic use*
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Melanoma / drug therapy*
  • Melanoma / mortality
  • Melanoma / secondary
  • Middle Aged
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / mortality
  • Survival Rate

Substances

  • Cimetidine